Amylyx Pharmaceuticals, Inc.
AMLX
$3.63
-$0.045-1.23%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -77.06% | -33.22% | 55.71% | 324.95% | 1,612.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -77.06% | -33.22% | 55.71% | 324.95% | 1,612.94% |
| Cost of Revenue | 48.88% | 137.06% | 138.03% | 165.35% | 59.29% |
| Gross Profit | -162.22% | -158.98% | -66.97% | 1,219.25% | 406.09% |
| SG&A Expenses | -39.30% | -15.53% | 14.02% | 39.59% | 48.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.58% | 55.20% | 74.55% | 92.30% | 52.96% |
| Operating Income | -911.12% | -3,422.89% | -119.12% | 47.76% | 119.27% |
| Income Before Tax | -656.45% | -4,620.35% | -129.99% | 55.79% | 127.48% |
| Income Tax Expenses | -107.82% | -48.52% | 58.10% | 1,087.34% | 549.35% |
| Earnings from Continuing Operations | -712.42% | -14,232.14% | -127.80% | 52.27% | 124.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -712.42% | -14,232.14% | -127.80% | 52.27% | 124.84% |
| EBIT | -911.12% | -3,422.89% | -119.12% | 47.76% | 119.27% |
| EBITDA | -886.73% | -3,912.70% | -119.99% | 48.31% | 119.86% |
| EPS Basic | -705.81% | -42,510.00% | -100.06% | 57.89% | 121.36% |
| Normalized Basic EPS | -795.39% | -11,279.09% | -108.16% | 55.64% | 119.14% |
| EPS Diluted | -734.56% | -16,371.12% | -97.18% | 56.86% | 120.37% |
| Normalized Diluted EPS | -823.85% | -49,272.00% | -106.26% | 54.66% | 118.38% |
| Average Basic Shares Outstanding | 1.41% | 1.73% | 4.97% | 8.43% | 14.95% |
| Average Diluted Shares Outstanding | -2.63% | -1.08% | 3.73% | 9.42% | 19.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
